Src Kinase Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Src kinase inhibitors are a class of pharmaceutical drugs that target the Src family of kinases, which are enzymes involved in cell signaling pathways. These inhibitors work by blocking the activity of Src kinases, thereby interfering with tumor growth, metastasis, and angiogenesis. Src kinase inhibitors have shown promise in the treatment of various diseases, particularly in the field of oncology. They are used in the management of cancer types such as breast cancer, lung cancer, colorectal cancer, and pancreatic cancer. According to the World Health Organization (WHO), breast cancer is the most common cancer among women worldwide, with an estimated 2.3 million new cases reported in 2020. Lung cancer is the leading cause of cancer-related deaths globally, accounting for 18.0% of all cancer deaths. Colorectal cancer is the third most common cancer worldwide, with approximately 1.9 million new cases reported in 2020. Pancreatic cancer has a high mortality rate, with only 10% of patients surviving for five years or longer after diagnosis. In Europe and the USA, breast cancer is a significant health concern. According to the European Society for Medical Oncology (ESMO), breast cancer accounted for 11.6% of all cancer cases in Europe in 2020. The American Cancer Society reports that breast cancer is the second leading cause of cancer-related deaths among women in the USA. Lung cancer is also prevalent in these regions, with the American Lung Association stating that it is the leading cause of cancer deaths in the USA.

The growth of the Src kinase inhibitor market is driven by factors such as advancements in cancer research, increasing demand for targeted therapies, and collaborations between pharmaceutical companies and research institutions. Companies such as Athenex, BMS, Generic mfg., AstraZeneca, Guangzhou Xiangxue Pharma, Hanmi, Almirall, Aptose Biosci, Avalyn Pharma, Basilea, CrystalGenomics, Exelixis, J&J, Nippon Shinyaku, Nuvectis Pharma, Pfizer, PharmaEssentia, Pulmatrix, ValiRx, ZAI Lab. cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, AstraZeneca is currently conducting a clinical trial of the drug AZD0530 for the treatment of urogenital neoplasms.

Key Developments

• In Oct 2022, Bristol-Myers Squibb completed a phase II trial of Dasatinib in Chronic myeloid leukemia and acute lymphoblastic leukemia (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China.
• In July 2022, Pfizer presented updated adverse events and efficacy data from a phase III BFORE trial Bosutinib in Chronic myeloid leukaemia at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022).

Approved Src Kinase Inhibitor Molecules

• Dasatinib
• Nintedanib
• Bosulif (bosutinib)
• Klisyri (tirbanibulin ointment)

Src Kinase Inhibitor Pipeline Molecules

• Tirbanibulin oral (KX2-391 oral)
• PUR1800
• XL228
• Ilginatinib (NS-018)
• Luxeptinib (CG-806)
• Nintedanib inhaled (AP02)
• AZD 0424
• BAL3833
• JNJ-26483327
• KX2-361
• NXP900
• TPX-0046
• VAL201
• Elzovantinib (TPX-0022)  

Clinical Activity and Development of Src Kinase Inhibitor

In the Src Kinase Inhibitor space, more than 10 companies are conducting more than 50 clinical trials in this category of drugs. For instance,

• In July 2022, Pfizer completed a phase I trial of Bosutinib in Healthy volunteers in Belgium.
• In Oct 2022, Bristol-Myers Squibb and M. D. Anderson Cancer Center, the Department of Defense completed a phase I trial of Dasatinib for Mesothelioma (First-line therapy, Early-stage disease, Mid-stage disease) in the USA.